2021
The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study
Post G, Lustgarten J. The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study. Topics In Companion Animal Medicine 2021, 46: 100616. PMID: 34864255, DOI: 10.1016/j.tcam.2021.100616.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCase-Control StudiesDog DiseasesDogsNeoplasmsPolysaccharidesProspective StudiesQuality of LifeConceptsOligo-FucoidanComplete blood countLife metricsLife scoresDouble-blinded studyMinimal adverse side effectsCase-control studyPlacebo control groupAdverse side effectsSignificant differencesQuality of lifeDiagnosis of cancerSerum biochemical parametersSerum biochemistry profilePlacebo groupUndergoing ChemotherapyProspective studyPhysical examinationBlood countCancer CenterFucoidan groupBlinded cliniciansLife QuestionnaireVeterinary patientsSide effects
2020
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2015
Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trials
2012
A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs
Vail D, von Euler H, Rusk A, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel E, Morris J, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C. A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. Journal Of Veterinary Internal Medicine 2012, 26: 598-607. PMID: 22390318, PMCID: PMC3837094, DOI: 10.1111/j.1939-1676.2012.00897.x.Peer-Reviewed Original ResearchConceptsMast cell tumorsAdverse eventsCell tumorsGrade 2Response ratePositive-controlled clinical trialMajority of AEsOverall response rateEarly phase studiesObserved response rateMechanism of actionAvailable TKIsPrimary endpointProspective multicenterSecondary endpointsSafety profileAE profileClinical trialsEffective treatmentPaclitaxel activityClinical importanceCombination protocolMicellar paclitaxelPaclitaxelLomustine